Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Sep 28, 2018	C	361,829	—	A	361,829	I	See Footnote
Common Stock^F1,F2	Sep 28, 2018	C	323,341	—	A	685,170	I	See Footnote
Common Stock^F1,F3,F2	Sep 28, 2018	C	412,583	—	A	1,170,010	I	See Footnote
Common Stock^F2	Sep 28, 2018	P	453,395	$15.00	A	1,623,405	I	See Footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series B Convertible Preferred Stock^F2,F1	—	Sep 28, 2018	C	7,500,000	D	—	—	Common Stock	361,829	I
Series B-1 Tranche A Convertible Preferred Stock^F2,F1	—	Sep 28, 2018	C	6,702,213	D	—	—	Common Stock	323,341	I
Series B-1 Tranche B Convertible Preferred Stock^F2,F1	—	Sep 28, 2018	C	8,552,024	D	—	—	Common Stock	412,583	I

Explanation of responses

F1Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
F2The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
F3This number includes an aggregate of 72,257 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.